Latest filing published 08 Jul 2015 for HAEMONETICS CORP, €753k.
Insider track record
No signal scores available.
Closed purchases
Based on 14 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -19.2%Entry US$38.81 · Close at T+365 US$31.34
- -3.0%Entry US$40.64 · Close at T+365 US$39.43
- +8.6%Entry US$35.72 · Close at T+365 US$38.81
- +40.2%Entry US$28.70 · Close at T+365 US$40.22
- +6.2%Entry US$33.63 · Close at T+365 US$35.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Peter M. Allen: trading record in brief
This profile gathers the share dealings of Peter M. Allen in Haemonetics Corp. In total, 87 filings cover trades dated from 1 May 2006 to 6 July 2015.
Both buying and selling appear: 14 purchases worth €120k, against 26 sales worth €10.1M. Sales outweigh purchases by €10.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 7 share grants and 23 option exercises. 2015 to date brings no purchases and 1 sale.
The median purchase comes to €9,597. Ninety days after publication, 14 purchases show a median change of +1.6%, with the price up in 57% of them. This is a record of the past, not a forecast.
The newest entry dates from 8 July 2015: an option exercise of €753k, in Haemonetics Corp. The latest purchase dates back some time: it was published 4,938 days ago, on 2 May 2013. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Peter M. Allen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 30,494 shares@ US$27.28Common StockSEC:0000313143-15-000047:0
- 30,494 shares@ US$40.19Common StockSEC:0000313143-15-000047:1
- 282 shares@ US$35.92Common StockSEC:0000313143-14-000117:0
- 289 shares@ US$36.22Common StockSEC:0000313143-14-000117:2
- 5,035 shares0Common StockSEC:0000313143-14-000104:0
- 264 shares@ US$35.44Common StockSEC:0000313143-14-000104:1
- 36,426 shares@ US$25.54Common StockSEC:0000313143-14-000103:0
- 36,426 shares@ US$35.22Common StockSEC:0000313143-14-000103:1
- 30,000 shares@ US$13.05Common StockSEC:0000313143-14-000044:0
- 30,000 shares@ US$30.70Common StockSEC:0000313143-14-000044:1
- 238 shares@ US$39.55Common StockSEC:0000313143-13-000180:0
- 417 shares@ US$39.55Common StockSEC:0000313143-13-000180:1
- 432 shares@ US$39.55Common StockSEC:0000313143-13-000180:2
- 3,240 shares0Common StockSEC:0000313143-13-000170:0
- 451 shares@ US$32.73Common StockSEC:0000313143-13-000069:0Canonical exit: 29 Jul 2013 (T+90)
- 22,828 shares@ US$10.73Common StockSEC:0000313143-13-000048:0
- 22,828 shares@ US$41.44Common StockSEC:0000313143-13-000048:1
- 33,288 shares@ US$26.38Common StockSEC:0000313143-13-000005:0
- 33,288 shares@ US$41.61Common StockSEC:0000313143-13-000005:1
- 20,000 shares@ US$10.73Common StockSEC:0000313143-13-000005:2
- 20,000 shares@ US$41.63Common StockSEC:0000313143-13-000005:3
- 113 shares@ US$61.46Common StockSEC:0000313143-12-000216:0Canonical exit: 30 Jan 2013 (T+90)
- 106 shares@ US$76.33Common StockSEC:0000313143-12-000204:0
- 191 shares@ US$76.33Common StockSEC:0000313143-12-000204:1
- 180 shares@ US$78.51Common StockSEC:0000313143-12-000190:0
25 of 84 declarations
